Appointment of US-based Chief Medical Officer

RNS Number : 4495K

ReNeuron Group plc

10 April 2018

 

 

10 April 2018

AIM: RENE

ReNeuron Group plc

("ReNeuron" or the "Company")

Appointment of US-based Chief Medical Officer

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that Dr Richard Beckman has joined the Company as Chief Medical Officer.  He replaces Dr Julian Howell who has left the Company to pursue another opportunity.

Dr Beckman brings to ReNeuron more than 25 years of executive and consultancy experience in drug and device development.  Prior to joining ReNeuron, Dr Beckman was the Chief Medical Officer of several innovative biotech and device firms, including Clearside, Ophthotech and Neurotech.  Prior to that, he had leadership roles at Alcon, Lux Bio, Becton Dickinson and Allergan.

Dr Beckman received his MD from the University of Michigan, completed a residency in ophthalmology at Henry Ford Hospital, and a glaucoma fellowship at the Mass. Eye and Ear Infirmary/Harvard University.   Prior to joining industry, he practised in academic medicine for three years at Cornell University Medical College and was in private practice for 10 years.

Dr Beckman will be based in ReNeuron's recently established US office in Boston, MA, where he will lead the Company's clinical and medical affairs team.

Commenting on Dr Beckman's appointment, Olav Hellebø, Chief Executive Officer of ReNeuron, said:

"I am delighted to welcome Rick to the Company's management team.  His many years' experience in medical practice and industry in the US will be invaluable to us as we build out our Boston team and increase our clinical activities in the US.  I would like to express my sincere thanks on behalf of the Company to Julian Howell who has led our clinical and medical team so skilfully.  We wish him well in his next endeavour."

Commenting on his appointment, Dr Beckman said:

"I am excited to be joining the experienced and talented team at ReNeuron.  I am grateful for the opportunity to help facilitate the translation of the Company's transformative technology to previously untreatable diseases in neurology and ophthalmology."

ENDS

ENQUIRIES:

ReNeuron	[phone]
Olav Hellebø , Chief Executive Officer
Michael Hunt, Chief Financial Officer
Buchanan	[phone]
Mark Court, Sophie Wills, Stephanie Watson
Stifel Nicolaus Europe Limited	[phone]
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)
N+1 Singer Advisory LLP	[phone]
Mark Taylor (Joint Broker)

About ReNeuron

ReNeuron is a leading, clinical-stage cell therapy development company.  Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.  

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments.  The Company has therapeutic candidates in clinical development for disability as a result of stroke and for the blindness-causing disease, retinitis pigmentosa.   

ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for drugs that would otherwise lack adequate capacity to penetrate to their site of action.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  Further information on ReNeuron and its products can be found at www.reneuron.com.

This announcement contains forward-looking statements with respect to the financial condition, results of operations and business achievements/performance of ReNeuron and certain of the plans and objectives of management of ReNeuron with respect thereto. These statements may generally, but not always, be identified by the use of words such as "should", "expects", "estimates", "believes" or similar expressions. This announcement also contains forward-looking statements attributed to certain third parties relating to their estimates regarding the growth of markets and demand for products. By their nature, forward-looking statements involve risk and uncertainty because they reflect ReNeuron's current expectations and assumptions as to future events and circumstances that may not prove accurate.  A number of factors could cause ReNeuron's actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements. 

 

END

 

 

MSCSFWFFSFASEDL